logo
Twitter
Discord
Email
logo
Janux Therapeutics, Inc.

Janux Therapeutics, Inc.

NASDAQ•JANX
CEO: Dr. David Alan Campbell Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-06-11
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Contact Information
10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, 92130, United States
858-751-4493
www.januxrx.com
Market Cap
$881.15M
P/E (TTM)
-9.2
40.7
Dividend Yield
--
52W High
$62.30
52W Low
$14.60
52W Range
0%
Rank62Top 82.4%
2.3
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2024

Financial Dashboard

Q3 2025 Data

Revenue

$10.00M+2177.90%
4-Quarter Trend

EPS

-$0.39-23.53%
4-Quarter Trend

FCF

-$12.95M+473.98%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Milestone Revenue Boost Collaboration revenue reached $10.0M for Q3 2025, driven by August milestone achievement with Merck. (Up $9.56M)
Strong Liquidity Position Cash, equivalents, and short-term investments totaled $989.8M as of September 30, 2025, supporting operations.
Increased R&D Investment Nine-month R&D expenses rose $46.7M to $94.3M, reflecting increased preclinical and clinical program costs.
G&A Expense Reduction General and administrative expenses decreased $1.9M for nine months, due to prior year stock compensation adjustments.

Risk Factors

Widening Operating Losses Net loss increased $32.9M to $81.7M for nine months, requiring substantial future capital infusion.
Escalating Development Costs R&D spending increased $46.7M over nine months, driven by advancing JANX007 and JANX008 programs.
Future Financing Required Current cash reserves are insufficient to fund candidates through regulatory approval, necessitating future capital raises.
Intellectual Property Uncertainty Success relies on patents; litigation risk exists, and scope/validity of IP protection remains uncertain.

Outlook

Advance Key Clinical Candidates Focus remains on advancing JANX007 in mCRPC and JANX008 in multiple solid cancers through Phase 1b.
Platform Program Generation Generating additional TRACTr, TRACIr, and ARM programs for future development pipeline expansion efforts.
Manage Public Company Costs Expect substantial increases in legal, accounting, and compliance costs associated with ongoing public company status.
Navigate Regulatory Landscape Future capital needs depend on successful navigation of evolving FDA/EMA requirements for product approvals.

Peer Comparison

Revenue (TTM)

Harmony Biosciences Holdings, Inc.HRMY
$825.94M
+21.1%
MannKind CorporationMNKD
$313.79M
+17.4%
Arcus Biosciences, Inc.RCUS
$240.00M
-8.7%

Gross Margin (Latest Quarter)

Viridian Therapeutics, Inc.VRDN
100.0%
+8043.1pp
Celldex Therapeutics, Inc.CLDX
100.0%
+31.9pp
Immatics N.V.IMTX
100.0%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
VRDN$2.67B-7.8-55.1%3.7%
EWTX$2.41B-16.7-30.6%0.7%
RCUS$2.40B-6.7-69.8%10.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 26, 2026
|
EPS:-$0.66
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $10.00M+2177.9%
    |
    EPS: $-0.39-23.5%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-0.55+400.0%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-0.38+26.7%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 27, 2025|
    Revenue: $10.59M+31.0%
    |
    EPS: $-1.28+3.0%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $439.00K-82.6%
    |
    EPS: $-0.51+104.0%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 7, 2024|
    Revenue: $8.90M+741.7%
    |
    EPS: $-0.11-73.8%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $1.25M-38.9%
    |
    EPS: $-0.30-28.6%
    Beat

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 8, 2024|
    Revenue: $8.08M-6.1%
    |
    EPS: $-1.32+13.2%
    Miss